Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Institutions
Pharmaceutical companies
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Guidelines
Oncology

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Radiation therapy: Regulatory framework and constraints

2022Regional

Europe

Original at the sourceAsk Osler about this guideline

On this page

Abstract
Source and rights

Abstract

The purpose of this article is to describe the regulatory framework of the radiotherapy practice in France.

Source and rights

Published by Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022. The guideline itself is at the source linked here.

doi.org/10.1016/j.canrad.2021.10.003

Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.

At a glance

Published: 2022
Applies to: 🇪🇺 Europe
Scope: Regional
Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
DOI: 10.1016/j.canrad.2021.10.003
PubMed: 34953694
Added to Prognia: 22 July 2026

More in oncology

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026Added 29 Jul 2026PodcastInfographic
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026Added 23 Jul 2026PodcastInfographic

Ask a question about this guideline.

Osler answers from this library and names the guideline behind every claim.

Screening for Cervical Cancer2026Added 23 Jul 2026PDF

Patient-Clinician CommunicationAmerican Society of Clinical Oncology (ASCO) · 2026Added 13 Jun 2026PodcastInfographic

Stage IV Non-Small Cell Lung Cancer without Driver AlterationsAmerican Society of Clinical Oncology (ASCO) · 2026Added 13 Jun 2026PodcastInfographic

International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancersEuropean Respiratory Society · 2026Added 23 Jul 2026

Updated clinical practice guidelines for the management of adult diffuse gliomasEuropean Respiratory Society · 2026Added 23 Jul 2026

SEMERGEN Position Statement on the management of the Oncologic Patient: Comprehensive Approach to Cardiotoxicity in Primary CareSEMERGEN · 2026Added 30 Jul 2026

ERAS 2026Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 updateERAS® Society · 2026Added 23 Jul 2026PDF

JSUO 2026Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic OncologyJapanese Society of Urologic Oncology · 2026Added 23 Jul 2026PDF

ASCO 2026Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO GuidelineAmerican Society of Clinical Oncology · 2026Added 18 Jul 2026PDF

Lung cancer screening with low-dose CT: definition of positive, indeterminate, and negative screen results. A nodule management recommendation from the European Society of Thoracic ImagingEuropean radiology · 2026Added 18 Jul 2026PDF